Prolong’s Sanguinate found to be safe and well-tolerated in Phase I study

6th October 2013 (Last Updated October 6th, 2013 18:30)

US-based biopharmaceutical firm Prolong Pharmaceuticals has reported that its intravenous therapeutic Sanguinate (PEGylated carboxyhemoglobin bovine) was found to be safe and well- tolerated in a Phase I study.

Sickle cells

US-based biopharmaceutical firm Prolong Pharmaceuticals has reported that its intravenous therapeutic Sanguinate (PEGylated carboxyhemoglobin bovine) was found to be safe and well-tolerated in a Phase I study.

The Phase I trial was a single centre, single-blind, placebo-controlled, single dose study of the safety, tolerability and pharmacokinetics of Sanguinate in healthy subjects.

During the trial, three dose levels of Sanguinate, including 80mg/kg, 120mg/kg and 160mg/kg were directed to three groups, with each including eight subjects, with six receiving active treatment (Sanguinate) and two received placebo comparator (saline).

Sanguinate, an intravenous therapeutic that joins the functions of a carbon monoxide releasing molecule (CORM) with an oxygen transfer agent (OTA), also acts as a plasma expander/flow enhancer.

According to the results from animal studies, low dose release of carbon monoxide promotes anti-inflammatory and anti-vasoconstriction effects, while oxygen is actively delivered to regions of low oxygen concentration (ischemia).

According to the company, Sanguinate was found to be well-tolerated and there were no serious adverse events in the study and no discontinuations due to adverse events.

Prolong Pharmaceuticals vice-president of clinical development Hemant Misra said the results from Sanguinate's Phase I trial found the product to be safe and well-tolerated.

"The safety data we have observed is superior to previously studied HBOCs (hemoglobin-based oxygen carriers)," Misra added.

"We are now moving forward into Phase II trials in patients with sickle cell disease, who suffer from painful vaso-occlusive crises."

"We are now moving forward into Phase II trials in patients with sickle cell disease, who suffer from painful vaso-occlusive crise."

The Phase I results were presented at the Joint Conference of the International Federation of Artificial Organs (IFAO) and the Japan Society of Artificial Organs (JSAO) in Yokohama, Japan.

Patients with sickle cell disease (SCD) have an inherited defect in their haemoglobin molecules, which leads to the development of several comorbidities, with severe, debilitating pain being the most common comorbidity.

These co-morbidities caused by a combination of severe oxygen deprivation and the toxicity of the patient's own haemoglobin released from their abnormally fragile red blood cells ultimately lead to cell death, tissue damage and organ dysfunction.

Sanguinate, which is designed to release therapeutic carbon monoxide and actively transfer oxygen to hypoxic tissue, is expected to interfere with these events early on so that these co-morbidities are reduced or prevented.

SCD affects virtually every organ system, leading to cardiovascular, renal, respiratory, musculoskeletal and nervous system complications.


Image: Sickle-cell disease is a genetic blood disorder with over dominance, characterized by red blood cells that assume an abnormal, rigid, sickle shape. Photo: courtesy of Dr Graham Beards.